Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18247929 | 0.84 | PDE2A (0.51) | PDE2A | |
| SCHEMBL16738661 | 0.77 | PDE2A (0.49) | PDE2A | |
| SCHEMBL3220152 | 0.74 | CYP3A4 (0.55) | PDE2A | |
| SCHEMBL21985680 | 0.72 | PDE2A (0.50) | PDE2A | |
| SCHEMBL16867827 | 0.68 | PDE2A (0.52) | PDE2A | |
| SCHEMBL13728327 | 0.67 | PDE2A (0.58) | PDE2A | |
| SCHEMBL10479181 | 0.64 | LMNA (0.62) | — | |
| SCHEMBL5384159 | 0.63 | GSK3B (0.64) | PDE2A | |
| SCHEMBL16505119 | 0.63 | LMNA (0.66) | — | |
| SCHEMBL10664400 | 0.63 | NUDT1 (0.40) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812041-B2 | Heterocyclic NF-κB inhibitors | 4SC AG (DE) | 2010-10-12 | — | — | US | disclosed |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | 4SC AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, NFKB2, NFRKB | PDE2A 4457/4885 |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | NFKBIA, NFKB2, NFRKB | PDE2A 4372/4885 |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFKB2, NFRKB | PDE2A 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.